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ABSTRACT 
Introduction: Tuberculosis (TB) is one of the most common infectious diseases 
worldwide. One third of the world’s population is infected with TB. Mycobacterium 
tuberculosis, the bacterium that causes TB, can infect the body and remain inactive 
(latent infection), or the infection can progress and cause the disease. Certain populations 
are at a particular risk to develop TB; these groups include persons infected with HIV, 
homeless persons, incarcerated individuals, and those who live in areas where TB is 
endemic, such as Southeast Asia. The standard treatment regimen to prevent progression 
to TB is the nine months of self-administered isoniazid (300 mg) (also known as the 9H 
regimen) for the treatment of latent TB infection (LTBI). However, a short regimen of 12 
weekly doses of isoniazid (900 mg) plus rifapentine (900 mg), (also known as the 3HP 
regimen) has been recently shown to be as effective as the standard regimen with higher 
treatment completion rates by the PREVENT TB trial.  
The objective of this analysis is to evaluate factors associated with non-completion of 
LTBI treatment among homeless participants enrolled in the PREVENT TB trial.  
Methods: The study population consisted of  6, 232 participants enrolled in the 
PREVENT TB trial after excluding participants enrolled in non-North American sites, 
pregnant women, and children. Non-completion of treatment was defined as receipt of:  
<11 of 12 doses within 10-16 weeks for 3HP or <240 of 270 doses within 35-52 weeks 
for 9H. Missing an early visit was defined as missing ≥1 of the first 3 observed doses in 
the 3HP regimen followed by receiving an observed dose during the treatment period; or 
missing ≥1 of the first 3 monthly visits in the 9H regimen, followed by a monthly visit at 
any time during treatment. Chi-square test, univariate and multivariate logistic regression 
analyses were conducted to evaluate demographic, clinical, social, and behavioral factors 
associated with non-completion of LTBI treatment in the homeless population by using 
SAS® version 9.3 (Cary, North Carolina).  
Results: The cohort for analysis included 6,232 participants (3HP = 3,230 and 
9H=3,002), of which 505 were homeless (8.1%). Most homeless participants were male 
(86.7%), born in the U.S. (87.1%), and African descendants (53.1%). The median age 
was 46 compared with 36 in the non-homeless group. Other characteristics associated 
with homelessness were unemployment, smoking, alcohol consumption, and use of 
concomitant medications. Homeless participants in both treatment regimens were more 
likely to be of African descent (p<0.001) and have a BMI classifying them as overweight 
(p<0.001). In the multivariate analysis, factors found to be statistically associated with 
LTBI treatment non-completion among homeless were: missing an early clinic visit 
compared to those who did not miss a clinic visit (OR: 4.57; 95%CI: 2.46, 8.49: 
p<0.0001), receiving the 9H regimen (OR: 2.11; 95%CI: 1.40, 3.18; p=0.0003),  born in 
non-US compared to those who were born in US (OR: 1.96; 95% CI: 1.1, 3.48; 
p=0.0220), and history of incarceration (OR: 1.69; 95%CI: 1.11, 2.57: p=0.0148).  
Conclusion: Homeless persons present many challenges in treatment for any disease, 
particularly one that requires lengthy treatment and follow-up such as tuberculosis, as 
well as prophylactic treatment for LTBI. Appropriate interventions to improve 
completion of LTBI treatment such as coordination with social and educational programs, 
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as well as with homeless shelters, could increase adherence among the homeless 
population. 
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1. INTRODUCTION 
 Tuberculosis (TB) is one of the most common infectious diseases worldwide. 
Although the rate of TB in the United States (U.S.) has declined significantly in recent 
years (2.96 cases per 100,000 persons) with a total of 9,421 cases in 2014, compared to 
10.4 cases/ 100, 000 26,673 cases, at the peak of the historical resurgence in 1992 (CDC, 
http://www.cdc.gov/tb/statistics/reports/2014/pdfs/tb-surveillance-2014-report.pdf). TB 
still remains a public health problem in the U.S. Efforts to control tuberculosis are 
challenged by a variety of factors. TB therefore persists as a public health concern, 
though on a smaller scale than that of the rest of the world. Its looming global presence 
highlights the importance of controlling it in the U.S. (CDC, 
http://www.cdc.gov/tb/topic/globaltb/default.htm). TB is caused by a bacterium, 
Mycobacterium tuberculosis, that is spread from person to person via droplet aerosols. 
TB mainly affects the lungs, but it can present in other parts of the body, such as the 
kidneys and brain (CDC, 
http://www.cdc.gov/tb/publications/faqs/qa_introduction.htm#anchor_two).  Despite the 
steady decline of TB in the U.S., there is a disproportionate burden of TB among racial 
and ethnic minorities (CDC, http://www.cdc.gov/tb/topic/globaltb/default.htm). Due to 
airborne spread, persons in close contact with persons with TB are thus at a high risk of 
acquiring TB. Once M. tuberculosis enters a person’s body, it has the capacity to cause 
TB disease, unless the person’s immune system suppresses the infection. There is an 
interplay of various factors that affects whether TB will develop into disease or it will 
remain latent. Persons with conditions that affect the immune system are at particular risk 
of developing TB when coming into contact with a known TB case. Such conditions 
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include: substance abuse, diabetes mellitus, silicosis, cancer of the head or neck, 
leukemia or Hodgkin’s disease, severe kidney disease, low body weight, treatment for 
rheumatoid arthritis or Crohn’s disease, and steroid or immunosuppressive treatments for 
organ transplants (CDC, 
http://www.cdc.gov/tb/publications/faqs/qa_introduction.htm#anchor_two). TB is a 
particular risk in HIV positive persons. HIV suppresses the immune system and increases 
the likelihood that latent TB will progress to active TB (CDC, 
http://www.cdc.gov/tb/publications/factseries/tbandhiv_eng.htm). These conditions, some 
more than others, are represented well in the U.S. The steady decline in TB in the U.S. 
should not diminish our efforts in eliminating TB.  
TB is unique among the spectrum of infectious diseases. It is contagious in 
droplet form and preys upon underserved people as well as those who reside in crowded 
living conditions. Its treatment is lengthy. TB is a worldwide burden in countries that are 
underdeveloped. While treatment is available for TB, many challenges inhibit people 
from seeking and complying with treatment. Worldwide, many people with active TB 
disease do not have access to health care and reside in suboptimal living conditions 
fraught with poor ventilation and crowding.  
Standard treatment regimens for active TB disease are lengthy (CDC, 
http://www.cdc.gov/tb/topic/treatment/default.htm#treatmentTBDisease). Six to nine 
months of antibiotics for treatment would be challenging for anyone to take, especially 
for someone who has adverse social factors such as homelessness and unemployment.  
Treatment regimens for latent TB are equally lengthy and demand compliance and 
consistency (CDC, http://www.cdc.gov/tb/topic/treatment/ltbi.htm). There is a risk for 
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dangerous health outcomes should patients decide to withdraw from treatment or not take 
the medicines appropriately. Perhaps these difficulties in treatment compliance have kept 
TB at the forefront of public health.  
Homeless people face many challenges both socially and medically. Their 
disadvantaged status does not bode well for their general well-being, especially their 
health. They live in crowded conditions, have limited access to medical care, and are 
underserved, which make them ideal repositories for the TB bacillus. TB is not a disease 
that is managed easily and it is especially difficult for homeless persons to receive health 
care. Requiring homeless persons to complete treatment for LTBI and active TB is 
challenging. 
2. LITERATURE REVIEW 
Data and Statistics 
One third of the world’s population is infected with M. tuberculosis. In its 
asymptomatic form, it is called latent TB infection (LTBI). While alarming, this statistic 
does not suggest that one third of the world’s population has active TB disease. One third 
of the population has been infected with the causative bacterium of TB but has not 
developed the disease and it will not transmit to others. The WHO also estimated that 
there were over 9 million new cases worldwide of TB in 2014 (WHO 
http://www.who.int/gho/tb/en/, 2015). The burden of TB is mostly in developing 
countries- 95% of all cases and deaths occur in developing countries.  
TB was accountable for the deaths of 1.1 million persons non-infected with 
Human Immunodeficiency Virus (HIV) and 0.36 million persons infected with HIV 
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(WHO, http://www.who.int/gho/tb/en/, 2015). HIV is a particular risk factor for the 
development of TB. In fact, persons infected with HIV have a 26 to 28 fold risk of 
developing TB. In addition, TB is the leading cause of death among persons infected with 
HIV, causing 25 percent of all HIV-associated deaths. Not only is infection of M. 
tuberculosis a threat to develop the disease, but death from TB is a threat to persons 
infected with HIV due to their immunocompromised status (WHO, 
http://www.who.int/hiv/topics/tb/tbhiv_facts_2015/en/).  
The Worldwide Geography of TB 
The distribution of TB varies by region. The most recent statistics demonstrate 
that the regions with the greatest number of new TB cases for 2013 were in Southeast 
Asia and Western Pacific regions (WHO, 
http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1). Yet 
Africa reported the greatest number of new cases per population, with 280 cases per 100, 
000 for 2013 (WHO, 
http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1). 
Although rates of TB still remain high in parts of the world where TB is endemic, such as 
Southeast Asia and the Western Pacific, part of the recent decline in TB rates can be 
attributed to the six point elimination strategy to reduce TB.  The WHO has embraced the 
END TB strategy, which employs prevention and research in an effort to engage partners 
from multiple sectors of the community with the common goal of eliminating TB (WHO, 
http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1). The 
goal of the END TB Strategy is to reduce deaths associated with TB as well as reduce TB 
incidence. Parts of the END TB Strategy include screening high-risk groups, treatment of 
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all patients with TB, management of TB in tandem with management of comorbidities, 
effective infection control, social support of those with TB in order to prevent 
discrimination from diagnosis, and integrating findings from the most recent research 
about TB as well as continuing to study TB treatments in order to ascertain the best 
treatment strategies for particular groups. 
The Burden of TB in the United States  
In the U.S., the majority of TB cases occur in persons who are foreign-born. In 2014, 
according to the CDC, 66% of the TB cases in the U.S. occurred among foreign-born persons. 
Thus, TB in the U.S. reflects in some ways the statistics of global TB. Therefore, most of the 
CDC’s TB control activities focused in high-burden countries can help to reduce the incidence of 
TB in the US (CDC http://www.cdc.gov/tb/topic/globaltb/default.htm). In this effort, the CDC 
provides technical assistance and research projects to improve TB control in several countries of 
the world with a high TB burden such as Botswana, Cambodia, China, Guyana, Ethiopia, Haiti, 
India, Kenya, Lesotho, Mexico, Peru, Philippines, Russia, South Africa, Thailand, and Vietnam.  
In the early 1900s, one of every seven people died of TB in the U.S. and Europe (CDC 
http://www.cdc.gov/tb/publications/faqs/qa_introduction.htm#anchor_two). After the discovery 
of antibiotics such as streptomycin around the 1940s, the incidence of new TB cases started to 
slowly decrease in the US (CDC 
http://www.cdc.gov/tb/publications/faqs/qa_introduction.htm#anchor_two). This led to a decrease 
in TB control activities around the nation. An important factor that contributed to an upswing of 
TB cases in the US was the emerging HIV epidemic in the early 1980s (Core Curriculum on TB: 
What the Clinician Should Know, 2011   ) and an influx of immigrants to the U.S. from countries 
where TB is endemic, such as Southeast Asia. This increase in TB cases supported the argument 
to increase funding for TB control and to focus on improving TB control activities. Fortunately, 
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with special attention, there has been a steady decline in TB in the U.S. since then and the 
incidence rate has gotten to the lowest in the history of the US. The CDC reports that 9, 421 cases 
of TB were reported in the US in 2014 (CDC http://www.cdc.gov/tb/statistics/default.htm). A 
lesson was presented, that in order to keep the disease contained, constant efforts are needed by 
TB programs and institutions. As programs contract, with tightening budgets, it remains to be 
seen whether the lesson was learned.  
Children and TB 
Pediatric TB is a public health problem of special interest since the finding of a 
new case indicates recent transmission, in most cases from a contagious adult with TB. 
2013 estimates from the WHO indicate that children contributed more than 500,000 new 
cases and that 74, 000 children die from TB annually (WHO, 
http://www.who.int/tb/challenges/childtb_factsheet.pdf?ua=1) . Also in 2013, a total of 
485 cases (5% of the total) were reported among children younger than 15 years of age in 
the U.S., while the proportion of pediatric TB could be as high as 20 % of the total cases 
of TB in high burden countries (CDC 
http://www.cdc.gov/tb/topic/populations/tbinchildren/default.htm ).  TB in children 
younger than 5 years of age is of clinical importance since life-threatening and the most 
severe forms of TB disease, such as disseminated TB and TB meningitis, develop at this 
age group.  
Once infected with the Mycobacterium tuberculosis, children are more likely to 
develop active TB disease than adults. This process also tends to occur more quickly in 
children (CDC http://www.cdc.gov/tb/topic/populations/tbinchildren/default.htm ).  
Symptoms of TB in children are similar to the symptoms of TB in adults.  
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The CDC has identified TB in children as a “hidden epidemic” in the world. 
Many underdeveloped countries do not have resources to adequately diagnose TB and 
thus the reporting of cases may be underestimated. Children also struggle to cough up the 
sputum that is needed to test for TB, making a TB diagnosis more difficult. The WHO 
estimates that 10 million children were orphaned by parental deaths from TB in 2010. 
Children are most often infected with TB by close contacts, such as family members 
(CDC http://www.cdc.gov/tb/topic/populations/tbinchildren/global.htm).  
Pathogenesis of TB 
TB is caused by the M. tuberculosis. It is spread from person to person via 
droplets from the person infected with M. tuberculosis. TB often affects the lungs, but 
can affect other parts of the body such as the bones, kidney and brain (CDC, 
http://www.cdc.gov/tb/topic/basics/default.htm, 2015). TB is highly infectious in nature 
because it is spread through airborne droplets from an infected person (Tuberculosis: 
Pathogenesis, Protection, and Control, 1994).  In fact, infectious particles with M. 
tuberculosis are emitted when an infected person speaks, coughs, or sneezes. There are 
variables in transmission of TB, including the “amount and concentration of bacilli 
present in the source case, the duration of exposure, and the aerodynamics of the inhaled 
particles” (Tuberculosis: Pathogenesis, Protection, and Control, 1994). Cough is a 
common symptom of pulmonary TB (Tuberculosis: Pathogenesis, Protection, and 
Control, 1994). The cough may begin as nonproductive but progress to a cough that is 
productive in sputum. The signs and symptoms of TB vary with the site involved, but in 
general the systemic signs of infection include fatigue, weight loss, and low grade fever. 
Diagnostic criteria for TB include sputum culture to confirm the presence of M. 
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tuberculosis as well as chest x-ray. Induced sputum, as well as bronchoscopy, are 
methods of obtaining a specimen if the patient is unable to produce sputum.  
Latent TB 
In addition to active TB disease, latent TB is also a concern. Initial acquisition of 
the M. tuberculosis bacterium does not develop into active TB disease in most persons 
(Jasmer, 2002). A person’s immunity often keeps the infection latent.  However, latent 
TB can easily progress to active TB if left untreated. It is therefore important that latent 
TB infection be treated with the same attention as active TB.  More than 80 percent of 
active TB cases in the U.S. stem from latent TB (Hartman-Adams, 2014). Co-infections 
that depress the immune system, or aging, may contribute to a flare up of the latent 
bacillus and develop into TB (Tuberculosis: Pathogenesis, Protection, and Control, 
1994). These first two years after infection pose the greatest threat to the development of 
active TB (Geiter, 2000). Failing to seek treatment for latent TB infection poses a five 
percent risk of developing active TB in the first two years after infection. There is a ten 
percent risk of developing active TB disease in individuals with normal immune systems 
who carry latent TB infection (Core Curriculum on Tuberculosis: What the Clinician 
Should Know, 2011). Treatment of latent TB is one of the strategies employed to 
eliminate TB in the U.S. Identifying and treating persons with latent TB may perhaps be 
the best method to reduce TB rates in high risk groups such as homeless persons 
(Bamrah, 2013). Despite the importance of identifying cases of latent TB, they are not as 
carefully measured as active TB cases (McAdam, 2009). Latent TB does not have the 
attendant symptoms that active TB does, and is often asymptomatic, thus causing some 
patients to prevent seeking or complying with treatment (Horsburgh Jr., 2004). Even 
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when treatment of latent TB is prescribed, treatment completion rates are low (Horsburgh 
Jr., 2004).  Lengthy regimens to treat LTBI as well as drug side effects are the main 
reasons for low treatment completion rates.  
Groups at Risk for TB 
 Certain populations are especially at risk for TB. These groups include drug 
users, homeless persons, and HIV positive individuals, among others. TB is a particular 
threat among those populations who reside in crowded conditions (CDC, 2015).  The 
WHO also lists the following groups of people as risk groups for TB: being an illicit drug 
user, being an immigrant from a country where TB is endemic, and those who have had 
recent contact with a person who has TB. These groups of people are often co-infected 
with HIV and latent TB infection (Lobato, 2005). HIV may depress the immune system 
and can cause that LTBI infection develop into active TB disease. Even if persons within 
these groups are identified, treatment compliance is problematic. Incarcerated persons are 
also a vulnerable population at risk for TB. The CDC cites several reasons that place 
inmates at risk of contracting TB: living conditions at correctional facilities such as 
overcrowding, close living quarters and inadequate ventilation, difficulty with follow up 
once a TB patient is released from prison, or when a TB patient is newly incarcerated, 
language barriers and barriers to health care, and HIV co-infection with TB. In the study 
by Lobato et al., a study of treatment completion and acceptability was conducted that 
enrolled jail inmates as well as homeless persons in five jails throughout the United 
States. In the recruitment phase of the study, nineteen percent declined treatment for 
LTBI. Overall, 561 1,211 participants completed treatment, resulting in a completion rate 
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of 46.3%. This study found most participants were male, black or Hispanic, were 
intravenous drug users, and were unemployed.  
HIV and TB Co-Infection 
HIV is a known risk factor for TB but little research has been conducted to 
elucidate the role that TB plays in the course of HIV. One African study sought to delve 
into this relationship. Eighty persons with HIV and in definite stages of TB (latent, no 
TB, and active TB) were included in this study. Persons with HIV had not yet begun 
antiretroviral therapy. Biomarker analysis as well as flow cytometric analysis were 
performed on the plasma of the subjects. Despite the small sample size, this study 
supported the idea that not only active TB patients had systemic inflammation but also 
that patients with latent TB infection had elevated T-cell activation (Sullivan, 2015). 
Therefore, latent TB poses a danger to persons with HIV by possibly accelerating the 
progression to AIDS and, therefore, earlier mortality.  
The presentation of TB in persons with HIV may be unique and not readily 
identifiable (Pimpin, 2011). TB and HIV co-infection also presents the challenge of 
disease management of both. Drug interactions, an increase in the number of pills to be 
taken, as well as potentially exacerbated medication side effects/ toxicity are some of the 
challenges faced by patients co-infected with HIV and TB. A systematic review found 
that risk factors for HIV-TB co-infection were “homelessness, imprisonment, alcohol 
abuse, sharing syringes, and close contact with a TB case” (Pimpin, 2011).  This study 
underlined the fact that risk factors for HIV and TB overlap. It also revealed that many 
studies did not routinely screen TB patients for HIV. More concerted efforts need to be 
undertaken to test TB patients for HIV. However, persons with TB may decline to be 
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tested for HIV, for various reasons. The CDC recommends that all patient with TB, 
including latent TB, be screened for HIV.  
Treatment for TB 
Treatment for active TB is mandatory to prevent transmission to the general 
public. Standard treatment regimens are lengthy and do not encourage compliance. 
Current standard treatment regimens for TB consist of a variety of drugs to be taken for 6 
to 9 months (CDC, 
http://www.cdc.gov/tb/topic/treatment/default.htm#treatmentTBDisease). Four drugs are 
considered to be the main lines of defense: isoniazid, rifampin, pyrazinamide, and 
ethambutol. These months of treatment are split up into the initiation phase and followed 
by the continuation phase (Blumberg, 2005). The continuation phase is either 4 or 7 
months (CDC, http://www.cdc.gov/tb/topic/treatment/default.htm#treatmentTBDisease). 
There are baseline as well as periodic clinic visits throughout the course of treatment to 
monitor response to therapy and to discover and address any adverse events or untoward 
symptoms that develop from treatment. Many treatment medications have side effects 
and adverse effects that can be dangerous or can inhibit treatment compliance. Such 
adverse effects include hepatotoxicity and thrombocytopenia (Jasmer, 2002). Any 
interruption or premature discontinuation of therapy may lead to drug resistant TB and 
continuation of TB disease in the individual (CDC, 
http://www.cdc.gov/tb/topic/drtb/default.htm,  2015). Directly observed therapy (DOT) 
has been an important part of treatment to encourage compliance. DOT means taking the 
prescribed medications in the presence of a healthcare provider. Implied in directly 
observed therapy is that participants understand the importance of complying with 
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treatment and showing up at assigned appointment times. Quarantines may be 
implemented for patients with active TB who do not wish to begin treatment. Quarantines 
are important to protect the health of the general public, as TB can be easily transmitted. 
Multi-Drug Resistant Tuberculosis (MDRTB) 
MDRTB is TB that is resistant at least to isoniazid and rifampicin, the two drugs 
that are the main line of defense against TB. In 2013, 480,000 people worldwide 
developed MDRTB (WHO, 
http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1). 
Inappropriate use of anti-TB drugs and treatment interruption can lead to MDRTB. 
MDRTB also can be acquired by airborne transmission from persons with MDRTB. 
Once TB has progressed to MDRTB, treatment options include additional anti-TB agents 
that may be less effective, may not be readily available, are expensive, and can cause 
multiple side effects (CDC, http://www.cdc.gov/tb/topic/drtb/default.htm). 
PREVENT TB Trial 
The PREVENT TB Trial, of the TB Trials Consortium (TBTC) was a 
randomized, open label phase 3 clinical trial that tested a shorter treatment regimen for 
latent TB infection (LTBI). This trial was conducted in the U.S., Canada, Brazil, and 
Spain and evaluated the standard treatment regimen of daily self-administered isoniazid 
(300 mg) for nine months (9H) against the shorter treatment regimen of once –weekly 
rifapentine (900 mg) and isoniazid (900 mg) for three months given under DOT (3HP). 
After all participants in the study were followed over 33 months, the trial showed that the 
short regimen was as effective as the standard regimen to treat LTBI (Sterling, 2011). 
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Treatment compliance was better in the shorter treatment regimen and thus supported the 
efficacy of a shorter treatment regimen for latent TB infection. Yet participants assigned 
to the combination therapy regimen were “more likely to have permanent drug 
discontinuation owing to an adverse event’ (Sterling, 2011). Some of these events were 
later identified as Systemic Drug Reactions, most of which presented as a flu-like 
syndrome. Groups at increased risk to develop this type of reaction were of white race, 
female sex, increased age, and lower BMI. Most of the reactions were mild and resolved 
within 24 hours (Sterling et al., 2015).  One of the main adverse events in the standard 
treatment regimen group was hepatotoxicity.  
Homeless Persons and Tuberculosis 
Homeless people have various factors that cause instability in their lives and, thus, 
prevent treatment compliance. Homeless people possess characteristics that, individually, 
place them at a higher risk of TB infection. Two main groups of persons encouraged to 
be tested for latent TB infection include persons recently in contact with known TB cases 
and those at risk of progression to active TB disease due to factors such as depressed 
immune systems and being a native from a country where TB is burdensome (Blumberg, 
2005). Homeless persons fall into both of these categories. Homeless persons lead 
itinerant lives, often moving in and out of homeless shelters where they are in close 
proximity to people with marginal health, at best. Homeless persons often have 
comorbidities, such as HIV, which fosters the acquisition of TB (Bamrah, 2013). Many 
often use alcohol and/or illicit drugs that impair their judgement (Bamrah, 2013). In 
addition, many are often plagued with legal troubles and are in and out of jail. Many 
homeless persons have no access to medical care (Bamrah, 2013). Yet even access to 
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medical care may not encourage homeless persons to seek treatment for latent TB. A 
study in Canada touched on some barriers that homeless persons face despite living in a 
country that has universal health coverage. Homeless persons may not be aware that they 
are at risk for TB and have had bad experiences within the health care system that prevent 
them from seeking care (Malejczyk, 2014). Mental illness is present in a number of 
homeless individuals (Shelton et al., 2009). Homeless participants often are malnourished 
and often go hungry (Baggett et al., 2010). Amidst these troubles, homeless people face 
many challenges in beginning and complying with treatment for TB. There may be a 
biological foundation that also predisposes homeless persons to TB; TB genotyping data 
posits that homelessness increases the transmission of TB (Malejczyk, 2014). As the 
instability of the economy continues, paired with the increase in immigrants to the U.S. 
from countries where TB is endemic, TB is a risk for the population at large. Considering 
the above factors, and considering how unstable their lives are, a shorter treatment is 
more advantageous for homeless people, as it will be easier for them to follow. 
It is especially important for homeless persons to be treated for latent TB 
considering the substantial financial burden that could result from lengthy, preventable 
hospitalizations attributable to TB (Marks, 2000). Since latent TB is largely 
asymptomatic, homeless persons are largely unaware that they carry latent TB and may 
not seek treatment until they have active symptoms. Thus, any manifestation of TB has 
then likely progressed to an advanced, active form, complications may have arisen that 
require lengthy hospitalizations, and transmission to others is likely to have occurred. In a 
cohort study, more homeless persons than non-homeless persons were incarcerated at the 
time of their diagnosis of TB (Marks, 2000).  This study also found that, when compared 
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to their hospitalized non-homeless counterparts, hospitalized homeless persons were 
more likely to have HIV, be substance abusers, and inject drugs. Homeless TB patients 
also had a higher rate of hospitalization and a longer median length of stay. Treatment 
compliance was higher among hospitalized TB patients than for non-hospitalized 
patients. 
It is difficult to get a true measure of the number of homeless persons in America 
and, in turn, an accurate rate of TB among homeless persons (Haddad, 2005). Many are 
not accounted for or are in and out of jail. Others lapse into periods of homelessness 
(Bamrah, 2013). The 2013 Bamrah et al. article found that homeless people had a tenfold 
increase in TB compared with the general population (36 to 47 out of 100000 homeless 
individuals versus 3.6 out of 100000 people in the general population for 2006-2010). 
This number is noteworthy, considering that homeless individuals comprise less than ten 
percent of the population in the U.S. 
Objective 
The objective of this analysis is to evaluate factors associated with non-
completion of treatment among homeless participants enrolled in the PREVENT TB trial. 
A better assessment of these factors may help to direct prevention strategies in the 
homeless population to increase completion of LTBI treatment.  
3. METHODS AND PROCEDURES 
These analyses examine data collected from the PREVENT TB trial of the TB 
Trials Consortium (TBTC), Centers for Disease Control and Prevention, Division of TB 
Elimination. The PREVENT TB Trial, “A Study of the Effectiveness and Tolerability of 
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Weekly Rifapentine/Isoniazid for Three Months Versus Daily Isoniazid for Nine Months 
for the Treatment of Latent TB Infection”, used two treatment regimens: 3HP: directly 
observed administration of isoniazid and rifapentine given weekly for twelve weeks and 
9H, a daily self-administered dose of isoniazid taken for nine months. 9H is the standard 
and most common treatment regimen of LTBI. A total of 8, 053 participants were 
enrolled in the study. Participants evaluated were infected with M. tuberculosis or were at 
high risk of developing TB. They all had the latent TB. Participants were deemed to have 
latent TB in any of the following four scenarios:  a recent conversion to a positive 
tuberculin skin test, HIV positive status with a positive tuberculin skin test, close contact 
with a culture confirmed TB patient, or a positive tuberculin skin test with an 
accompanying chest radiograph that shows fibrosis. After excluding non-North American 
sites, pregnant women, persons less than 18 years of age, and ineligible persons, the 
combined cohort consisted of 6, 232 individuals (Figure 1). Only sites within the U.S. 
and Canada were examined in this analysis for relative homogeneity of health practices in 
the north-American region.  
Subjects were assigned to study groups according to simple unrestricted 
randomization. In group settings (such as households or homeless shelters), subjects 
could be placed on the same regimen as the first person in the group (cluster). That way, 
everyone in the cluster received the same treatment, as they were within contact of one 
another and are comparable amongst themselves. In this way, only the first person in the 
cluster was randomized in the study but everyone within the cluster received treatment. 
Randomization was stratified by HIV status and enrolling site. Throughout the course of 
the study, participants had a series of clinical evaluations. Participants in the 3HP DOT 
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treatment regimen had clinical evaluations at weeks 4, 8, and 12. Participants in the 9H 
treatment regimen underwent monthly clinical evaluations. Each clinical evaluation 
assessed such items as weight, adverse reactions, new diagnoses or hospitalizations, use 
of concomitant medications, and methadone withdrawal. Adverse events were recorded if 
their onset was at any time during the study, as well as up to 60 days after administration 
of the last study dose. For the 3HP regimen, adherence was measured by therapy records 
for the study drugs. For the 9H regimen, adherence was measured by pill count and self- 
report.  
Factors associated with non-completion were categorized as demographic 
(including age, sex, race, ethnicity, country of origin, unemployment, homeless, history 
of incarceration, need for an interpreter), clinical (body mass index, HIV status, 
concomitant medication use, indication for LTBI treatment, cirrhosis, methadone 
treatment), social (alcohol consumption, smoking status, intravenous drug use), or 
behavioral (missed visits, treatment regimen, or enrollment site). 
The classification of not completing treatment was as follows: in the 3HP 
regimen, missing at least one study drug dose within 10 to 16 weeks; in the 9H treatment 
regimen, missing thirty doses within 35 to 53 weeks. In addition to not completing 
treatment, missing clinic visits were also tracked. Missing an early visit was defined for 
the two treatment regimens as follows: missing 1 or more than 1 of the first 3 observed 
doses in the 3HP-DOT regimen followed by receiving an observed dose during the 
course of the treatment period; in the 9H-SAT regimen missing 1 or more than one of the 
first 3 monthly visits, followed by a monthly visit at any time during the treatment period. 
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Alcohol abuse was classified as a score of at least 2 on the CAGE questionnaire. 
Participants were asked if they currently smoked at the time of enrollment.   
All participants provided written informed consent. The study protocol was 
reviewed and approved by the institutional review boards at the Centers for Disease 
Control and Prevention and at each of the participating clinical sites. 
Non-completion of treatment (NCT) proportions were calculated for all potential 
factors evaluated. Age was categorized as above or below the median age of the study 
population (38 years). Odds ratios (ORs), 95% confidence intervals (CIs), and P values 
were calculated for potential risk factors for NCT. All factors with a p-value  0.2, as 
well as those that were near significant, in the univariate analysis were included in the 
multivariate model, in addition to age and sex. We performed backward elimination to 
select statistically significant factors with p-value < 0.05. Univariate and multivariate 
analyses were conducted among various factors outlined above using SAS® version 9.3 
(SAS Institute, Inc., Cary, North Carolina). 
4. RESULTS 
The combined cohort for analysis included 6,232 participants (3HP = 3,230 and 
9H=3,002) (Figure 1), of which 505 were homeless (8.1%, 3HP = 289, 9H = 216). Most 
homeless participants were male (86.7%), born in the U.S. (87.1%), and of African 
descent (53.1%). The median age was 46 compared with 36 in the non-homeless group. 
Other characteristics associated with homelessness were unemployment, smoking, 
alcohol consumption, and use of concomitant medications. Additional demographic 
characteristics can be found in Table 1. 
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Comparison of demographic factors among homeless participants, stratified by 
treatment regimen are shown in Table 2. Most of the factors evaluated in this table shown 
to be non-significant. Thus, the distribution of factors among the homeless participants 
was similar in both treatment regimens.  The table also shows that most homeless 
participants in both treatment regimens were more likely to be of African descent 
(124/216, 57.41% for the 9H regimen and 144/289, 49.83% for the 3HP regimen) and 
have a BMI classifying them as overweight (87/216, 40.28% for the 9H regimen versus 
112/289, 38.75%  for the 3HP regimen). 
Table 3 shows treatment completion among all of the studied participants, 
stratified by treatment arm and homelessness. Homeless participants assigned to the 3HP 
regimen, were more likely to complete LTBI treatment (227/289, 79%, p<0.001) than 
homeless participants assigned to the 9H regimen (132/216, 61%, p<0.001). 
Tables 4A and 4B show the reasons for non-completion of treatment by treatment 
regimen. In the 9H regimen, the most frequent factor was being lost for more than 3 
months (40%), followed by the category classified as ‘other’ (26%) and drug toxicities 
(12%). In the 3HP regimen, the most frequent reason for not completing treatment among 
homeless persons was the ‘other’ reason (27%), followed by drug toxicities and being 
lost for more than 3 months (20%).  
Tables 4C and 4D present classification of the “other” reasons presented in Tables 
4 A and 4B. For the 9H regimen, incarceration and loss of a participant accounted for the 
other reason. This was also the case with the “other” reason in the 3HP regimen. Even 
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after classification of the “other” variable, there were still unknown/ missing reasons 
within the “other” variable for non-completion of treatment. 
Results from a univariate analysis within the homeless population are presented in 
Table 5.  Participants assigned to the 9H regimen, were more likely not to complete 
treatment compared to participants assigned to receive the 3HP regimen (OR: 2.1; 
95%CI: 1.4, 3.18; p<0.001). Other factors associated with non-completion of treatment 
were contact of a TB case as a reason to receive LTBI treatment (OR: 1.64; 95%CI: 1.04, 
2.58; p=0.03) and missing an early clinic visit (OR: 5.3; 95%CI: 2.71, 10.4; p<0.0001).  
Some factors were almost significant, such as ethnicity (OR 1.70, 95% CI: 0.96 – 3.01, 
p=0.072), birthplace (OR 1.65, 95% CI 0.96 – 2.83, p= 0.07) , and history of 
incarceration (OR 1.635, 95% CI 0.97 – 2.12, p = 0.07). 
Multivariate analysis is displayed in Table 6. The multivariate model assesses the 
association of certain factors with the outcome of non-completion of LTBI treatment 
while controlling for other factors. Factors found to be statistically associated with 
treatment non-completion among homeless were: the 9H regimen (OR: 2.11; 95%CI: 
1.40, 3.18; p=0.0003), born in non-US compared to those who were born in US countries 
(OR: 1.96; 95%CI: 1.1, 3.48; p=0.0220), history of incarceration (OR: 1.69 ; 95%CI: 
1.11, 2.57: p=0.0148), and missing an early clinic visit compared to those who did not 
missed a clinic visit (OR: 4.57; 95% CI: 2.46, 8.49: p<0.0001). Similar results were 
obtained when the same analysis was applied to the population selected by the first 
participant enrolled in a cluster. (Table S5).  
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Table 7 presents the homeless participants stratified by regimen and site. Sites 
located in Texas and Washington State had the highest proportion of enrollment of 
homeless participants. Table 8 shows the sizes of the different clusters enrolled, stratified 
by homeless status. The largest cluster was the one with 31 participants (29 in the 3HP 
and 2 in the 9H regimen).  
Table 9 shows the size of clusters among only the homeless population, stratified 
by treatment regimen. The largest cluster was the one with 29 participants enrolled, all in 
the 3HP regimen.  
Table S1 presents characteristics of the first participant enrolled in a cluster, 
stratified by homeless status. Homeless participants were more likely to be male (84.9%), 
born in the U.S. (87.3%), being African descent (58.3%) and be of non-Hispanic origin 
(89%). The median age in the homeless population was 46 compared to 37 in the non-
homeless population (p<0.001).  They were also more likely to be unemployed, being a 
current smoker and report alcohol consumption at the time of enrollment (p<0.001).  
Table S2 details the characteristics of the clustered homeless participants, 
stratified by treatment regimen. Most of the factors evaluated were equally distributed 
between both regimens indicating that the effects of randomization were still present after 
some exclusions were done to define the study population of this study.  
Table S3 shows the univariate analyses among the clustered homeless 
participants. The most significant factor was missed an early clinic visit associated with 
non-completion of treatment (OR: 5.3; 95%CI: 2.71, 10.4; p<0.001). Other factors 
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associated with non-completion of treatment were being Hispanic (OR: 2.1; 95%CI: 1.13, 
3.98; p=0.02), born in a non-US country (OR: 2.1; 95%CI: 1.14, 3.70; p=0.02), contact of 
a TB case as the reason to receive LTBI treatment (OR: 1.64; 95% CI: 1.04, 2.58; 
p=0.03), and missed an early clinic visit (OR: 5.3; 95%CI: 2.71, 10.4; p<0.001), 
Table S4 shows the multivariate analyses for non-completion of treatment among 
the first participant enrolled in the cluster. Among the clustered homeless participants, the 
most significant factor associated with non-completion of treatment was missed early 
clinic visit (OR: 5.2; 95%CI: 2.55, 10.46; p<0.001), followed by born in the US 
compared to those born in non-U.S. countries (OR: 2.81; 95%CI: 1.48, 5.35; p=0.0016), 
receiving 3HP compared to 9H regimen (OR: 2.2; 95%CI: 1.41, 3.53; p=0.0006), and 
history of incarceration (OR: 2.1; 95%CI: 1.28, 3.32; p=0.0029).  
5. DISCUSSION 
The most significant factor in the multivariate analysis for non-completion of 
treatment in the homeless population was missing an early clinic visit (OR: 4.57, 95% CI: 
2.46- 8.49; p<0.0001) after controlling for other factors.  This result is consistent when 
the analysis was limited to the first participant enrolled in a cluster. This finding follows 
logic, as it questions the compliance of the participants. Monitoring missed clinic visits is 
important to ensure that treatment is being followed as prescribed and to monitor for any 
potential adverse events. The shorter 3HP regimen was also associated with better 
treatment compliance (OR: 2.1; 95% CI: 1.42- 3.18; p=0.0003). Thus, homeless 
participants in the 9H regimen were 2.13 times more likely not to complete treatment 
compared to 3HP. The 3HP regimen is more advantageous than 9H for homeless persons, 
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as it requires less of a time commitment from them. Incarceration also plays a role in 
determining treatment compliance. A homeless person with history of incarceration may 
have other social factors that may prevent him or her from complying with treatment. In 
addition, there is the possibility that a homeless person with history of incarceration may 
interrupt treatment due to a new incarceration. The interruption in treatment is 
problematic on many levels. Although alcohol use was not significantly associated with 
non-completion of treatment in the univariate analysis, alcohol use may impair the 
judgment of a person and also may contribute to hepatotoxicity with treatment 
medications.  
Nuzzo et al. found that LTBI treatment completion was highest among refugees 
(296/333, 89%) and also found some evidence that treatment completion was higher 
among those persons who received a shorter treatment regimen. However, this finding 
was not statistically significant in this analysis after adjusting for other factors.  
Our study found that many homeless persons either used or abused alcohol (use: 
223/501=44.2%, abuse:181/501=35.8%). A report on homelessness (Haddad, 2005) 
found that excessive alcohol use was greater among homeless than non-homeless 
persons. This is concerning, considering that the drugs used in this study may cause 
hepatotoxicity. Hepatotoxicity is exacerbated by alcohol use, especially by alcohol abuse. 
This report also found that more non-homeless persons (84%) completed TB treatment 
compared to homeless persons (77%) which may be a factor for increasing the 
transmission of M. tuberculosis in this population. 
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The findings in these analyses are supported by a similar study that examined 
both treatment initiation and continuation of LTBI treatment. This study found that most 
participants were foreign-born and a racial/ethnic minority and those more likely to 
initiate treatment had a history of incarceration (Goswami, 2012). The study also showed 
that treatment completion was more likely to occur among non-smokers. This study noted 
that initiating, rather than completing, LTBI treatment was more challenging. 
The burden of TB among males, particularly homeless males, is supported by a 
cross-sectional Korean study (Lee, 2013).  Out of the 313 homeless participants, 309 of 
them were male. This study also supported the fact that homeless persons carry a 
disproportionate burden of TB when compared to the general population.  
As our study favors combination therapy for the treatment of LTBI in the 
homeless population, the administration of the combination therapy under directly 
observed therapy may increase compliance. Increasing LTBI treatment completion in 
persons at risk of developing TB is an important component of TB control/elimination 
strategy.  
Limitations 
 One limitation of the study was not examining the effect of certain comorbidities 
such as diabetes on examining treatment completion. Studies are emerging that show the 
link between Type II diabetes and TB  (Martínez-Aguilar et al., 2015); (Restrepo & 
Schlesinger, 2014). This is noteworthy, as most participants in this study had a BMI 
categorizing them as overweight and most homeless participants were Africa-American. 
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Type II diabetes is a particular burden among those with a high BMI as well as African-
Americans, so its distribution among participants in this study would have been 
compelling to explore.  
 Injection drug use as well as methadone use were self-reported. Due to the 
sensitive nature of these questions, participants may not have been forthcoming with this 
information. This may have resulted in misclassification bias. 
Another limitation is that the study assumed that those who were assigned to the 
9H regimen took their doses as prescribed without being under the direct observation of a 
clinician. The counting of 9H doses relied on the participant’s report. DOT completion 
reporting is likely to be more reliable. Self-reported completion might overestimate actual 
completion, causing the treatment completion differences between treatment regimens 
reported in this study to be conservative underestimates. 
Among both the homeless and non-homeless participants, quite a number of them 
have an unknown HIV status (159/505, 31.49% among homeless participants versus 
2839/5727, 49.57% among non-homeless participants). Many characteristics of homeless 
persons that place them at risk for TB are also risk factors for HIV. Therefore, it would 
be beneficial to obtain an HIV test on these participants and initiate anti-retroviral 
therapy, if they are HIV positive. HIV status is especially important considering it is a 
known risk factor for TB. In one study, forty percent of incident TB cases were 
seropositive for HIV (Moss, 2000).  
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Less than ten percent of the study participants enrolled in the PREVENT TB trial 
were homeless (6%), which may limit these analyses. However, the number of homeless 
persons in the study are comparable with estimates of homeless persons in the United 
States of 842,000 people, or one percent of the population.  (National Coalition for the 
Homeless, http://www.nationalhomeless.org/factsheets/How_Many.html). 
6. CONCLUSION 
Early, effective treatment for LTBI among high risk groups such as homeless 
persons is challenging but in the best interest of the general public. Better prevention 
strategies and coordination among different sectors of public health need to be 
implemented in order to ensure compliance of treatment. Unique approaches need to be 
implemented towards homeless persons so they understand the gravity of being treated 
for latent TB. The PREVENT TB trial, as well as other studies, have supported better 
compliance rates with shorter LTBI treatment regimens. Therefore, every effort should be 
made to offer shorter treatment regimens to homeless persons and those persons in whom 
compliance may be challenging. A more seamless treatment regimen should also be 
available for homeless persons with history of incarceration. Homelessness as well as 
incarceration have high recidivism rates so follow-up is important in those persons who 
vacillate between the two states. Homeless and incarcerated individuals live on the 
fringes of society so it is a particular challenge for people to invest in them. Focused 
strategies that encourage treatment compliance will surely make the elimination of TB 
more of a possibility.  
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Figure 1. Flow Chart of Participants Evaluated for Factors Associated with Non-
completion of Latent TB Infection Treatment in Homeless Participants Enrolled in 
The PREVENT TB Study – North American Sites (from the Tuberculosis Trials 
Consortium) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviation: AE, adverse event 
a This analysis includes enrolling sites from U.S. and Canada. Enrolling sites from Brazil and Spain were 
excluded.  
b This analysis considers adults age 18 or older. 
c PREVENT TB Study reasons for ineligibility: source case resistant isoniazid/rifampin (50%), source case culture 
negative (31%), other (19%). Exclusion criteria: a) current confirmed TB, b) suspected TB, c) TB 
   resistant to isoniazid or rifampin in the source case, d) history of treatment for >14 consecutive days with a 
rifamycin or  
   >30 consecutive days with isoniazid during the previous 2 years, e) documented history of completing adequate 
treatment  for active TB or latent M. TB infection in a HIV-seronegative person, f) history of sensitivity/intolerance 
   to isoniazid or rifamycins, g) serum aspartate aminotransferase (AST) >5 times the upper limit of normal (ULN) if 
AST  was determined, h) pregnant or lactating females, i) persons currently receiving or planning to receive HIV-1 
therapy  
   within 90 days after enrollment, or j) weight < 10.0 kg. 
d Reasons for LTBI treatment (not-mutually exclusive): contact of infectious TB case (n = 4,156), tuberculin skin 
test  converter (n = 2,205), HIV positive (n = 140), and fibrosis (n = 181).   
 
 
Participants enrolled in the 
PREVENT TB Study 
from 05 June 2001 to 15 February 2008 
n = 8,053 
Non-North American sitesa (n = 920) 
 
Pregnancies (n = 114) 
Persons < 18 years of ageb (n = 592) 
Ineligibles c (n = 195) 
 
n = 7,133 
n = 6,541 
Combined cohort for analysis 
(n = 6,232) d 
3HP (n = 3,230) 9H (n = 3,002) 
 
                             
 
  n = 6,427 
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  Table 1. Demographics Characteristics Among Homeless and Non-Homeless 
  Participants in the United States and Canadian Sites in the PREVENT TB Trial 
(N= 6232) 
Factor Homeless  
n=505 (%) 
Non-homeless 
n= 5727 (%) 
p-value 
Sex 
Male 
Female 
 
438 (86.73) 
67 (13.27) 
 
3056 (53.36) 
2671 (46.64) 
<0.001 
Age-years 
Median 
Interquartile range 
 
46 
40, 52 
 
36 
27, 47 
<0.001 a 
 
Siteb 
                             Other 
sites 
                                   Site 
70 
 
488 (96.63) 
17 (3.37) 
 
5398 (94.26) 
329 (5.74) 
<0.0001  
Birthplace in the U.S. 
Yes 
No 
 
440 (87.13) 
65 (12.87) 
 
2050 (35.80) 
3677 (64.20) 
<0.001 
Race 
African descendent 
Asian 
White 
Other d 
 
268 (53.07) 
11 (2.18) 
186 (36.83) 
40 (7.92) 
 
1361 (23.76) 
869 (15.17) 
3283 (57.32) 
   214 (3.74)        
<0.001 
Ethnicity  
Hispanic 
Non-Hispanic 
 
56 (11.09) 
449 (88.91) 
 
2546 (44.46) 
3181 (55.54) 
<0.001 
BMI-numeric 
Median 
Interquartile range 
 
27 
(24,31) 
 
27 
(24,31) 
0.5223 a 
BMI Category 
<18.5 
18.5 – 24.9 
25-29.9 
>30 
 
9 (1.78) 
146 (28.91) 
199 (39.41) 
151 (29.90) 
 
95 (1.66) 
1639 (28.62) 
2022 (35.31) 
1971 (34.42) 
0.1701 
Education Category  
8th grade or less 
8th grade to some college 
College degree or greater 
 
44 (8.71) 
432 (85.54) 
29 (5.74) 
 
1084 (18.93) 
3514 (61.36) 
1129 (19.71) 
<0.001 
History of incarceration e 
Yes 
No 
 
194 (38.42) 
311 (61.58) 
 
199 (3.47) 
5528 (96.53) 
<0.001 
Unemployment 
Yes 
No 
 
331 (65.54) 
174 (34.46) 
 
444 (7.75) 
5283 (92.25) 
<0.001 
Latent TB contact    
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Factor Homeless  
n=505 (%) 
Non-homeless 
n= 5727 (%) 
p-value 
Yes  
No 
348 (68.91) 
157 (31.09) 
3808 (66.49) 
1919 (33.51) 
0.2689 
Latent TB fibrosis 
Yes 
No 
 
1 (0.20) 
504 (99.80) 
 
180 (3.14) 
5547 (96.86) 
<0.001c 
Latent TB HIV positive 
Yes 
No 
 
33 (6.53) 
472 (93.47) 
 
107 (1.87) 
5620 (98.13) 
<0.001 
Latent TB TST converter 
Yes 
No 
 
210 (41.58) 
295 (58.42) 
 
1995 (34.83) 
3732 (65.17) 
0.0024 
HIV status 
Positive 
Negative 
Unknown 
 
36 (7.13) 
310 (61.39) 
159 (31.49) 
 
112 (1.96) 
2776 (48.47) 
2839 (49.57) 
<0.001 
Smoking at enrollment 
Yes 
No 
 
370 (73.27) 
135(26.73) 
 
1540 (26.89) 
4187 (73.11) 
<0.001 
Alcohol consumption f 
                              use 
abuse 
no 
 
223 (44.16) 
181 (35.84) 
101(20) 
 
2675 (46.71) 
302 (5.27) 
2750 (48.02) 
<0.001g 
Injection drug use  
Yes 
No 
 
111 (21.98) 
394 (78.02) 
 
156 (2.72) 
5571 (97.28) 
<0.001 
 
Methadone treatment 
 Yes 
No 
 
25 (4.95) 
480 (95.05) 
 
112 (1.96) 
5615 (98.04) 
<0.001 
Use of concomitant 
medications                     
Yes 
No 
 
288 (57.03) 
217 (42.97) 
 
2764 (48.26) 
2963 (51.74) 
0.0002 
Use of a translator 
Yes 
No 
 
25 (4.95) 
480 (95.05) 
 
1616 (28.22) 
4111 (71.78) 
<0.001 
Liver disease 
Yes 
No 
 
101 (20) 
404 (80) 
 
151 (2.64) 
5576 (97.36) 
<0.001 
Abbreviations: 3HP-DOT, 3 months of directly observed, once-weekly rifapentine (maximum dose, 900 
mg)  
plus isoniazid (maximum dose 300 mg); 9H-SAT, 9 months of daily self-administered isoniazid; LTBI: 
latent  
TB infection. HIV: human immunodeficiency virus. BMI: body mass index.  TST: tuberculin skin test. 
a  Median Two-Sample Test using the proc npar1way SAS procedure.  
b  The variable site was categorized arbitrarily taking site with the highest number (70) as the reference.  
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cFisher’s exact test 
d Includes North American Indian and other participants in the United States and Canada. 
     e  History of residing within a correctional institution for ≥ 1 month before enrollment.  
f Use: affirmative response to a question asking whether the participant ever drank alcoholic beverages. 
Abuse:  
score of ≥2 on the CAGE questionnaire.  
g Mantel-Haenszel Chi-Square 
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Table 2. Demographic Characteristics of Homeless Participants in the PREVENT 
TB Trial, Stratified by Treatment Regimen (N=505) 
Factor Treatment 
Regimen 9H SAT 
n=216 
Treatment 
Regimen 3HP 
DOT 
n=289 
p-value 
Sex 
Male 
Female 
 
182 (84.26) 
34 (15.74) 
 
256 (88.58) 
33 (11.42) 
0.1566 
Age-years 
Median 
Interquartile range 
 
45 
40,53 
 
47 
40,52 
0.5916a 
Birthplace in the U.S. 
Yes 
No 
 
183 (84.72) 
33 (15.28) 
 
257 (88.93) 
32 (11.07) 
0.1627 
Race 
African descendent 
Asian 
White 
Otherc 
 
124 (57.41) 
7 (3.24) 
81 (37.50) 
4 (1.85) 
 
144 (49.83) 
4 (1.38) 
105 (36.33) 
36 (12.46) 
<0.001b 
Ethnicity  
Hispanic 
Non-Hispanic 
 
27 (12.50) 
189 (87.50) 
 
29 (10.03) 
260 (89.97) 
0.3827 
BMI  
Median 
Interquartile range 
 
26 
(23, 29) 
 
28 
(24, 32) 
0.0284a 
BMI category 
<18.5 
18.5 – 24.9 
25-29.9 
>30 
 
7 (3.24) 
72 (33.33) 
87 (40.28) 
50 (23.15) 
 
2 (0.69) 
74 (25.61) 
112 (38.75) 
101 (34.95) 
<0.001b 
Education category 
8th grade or less 
8th grade to some 
college 
College degree or 
greater 
 
23 (10.65) 
177 (81.94) 
16 (7.41) 
 
21 (7.27) 
255 (88.24) 
13 (4.50) 
0.1343 
History of 
incarcerationd 
Yes 
No 
 
77 (35.65) 
139 (64.35) 
 
117 (40.48) 
172 (59.52) 
0.2690 
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Factor Treatment 
Regimen 9H SAT 
n=216 
Treatment 
Regimen 3HP 
DOT 
n=289 
p-value 
Unemployment  
Yes 
No 
 
140 (64.81) 
76 (35.19) 
 
191 (66.09) 
98 (33.91) 
0.7655 
Latent TB contact  
Yes 
No 
 
137 (63.43) 
79 (36.57) 
 
211 (73.01) 
78 (26.99) 
0.0213 
 
Latent TB fibrosis 
Yes 
No 
 
0 (0) 
216 (100) 
 
1 (0.35) 
288 (99.65) 
0.5723b 
Latent TB HIV positive 
Yes 
No 
 
19 (8.80) 
197 (91.20) 
 
14 (4.84) 
275 (95.16) 
0.0754 
Latent TB TST 
converter 
Yes 
No 
 
91 (42.13) 
125 (57.87) 
 
119 (41.18) 
170 (58.82) 
0.8298 
HIV status  
Positive 
Negative  
Unknown 
 
19 (8.80) 
126 (58.33) 
71 (32.87) 
 
17 (5.88) 
184 (63.67) 
88 (30.45) 
0.3206 
Smoking at Enrollment 
Yes  
No 
 
157 (72.69) 
59 (27.31) 
 
213 (73.70) 
76 (26.30) 
0.7983 
Alcohol Consumption e 
Use 
Abuse 
No 
 
92 (42.59) 
68 (31.48) 
56 (25.93) 
 
131 (45.33) 
113 (39.10) 
45 (15.57) 
0.0569f 
Injection drug use  
Yes 
No 
 
50 (23.15) 
166 (76.85) 
 
61 (21.11) 
228 (78.89) 
0.5837 
 
Methadone treatment  
Yes 
No 
 
17 (7.87) 
199 (92.13) 
 
8 (2.77) 
281 (97.23) 
0.0089 
Use of a translator  
Yes 
No 
 
13 (6.02) 
203 (93.98) 
 
12 (4.15) 
277 (95.85) 
0.3388 
Liver disease  
Yes 
No 
 
51 (23.61) 
165 (76.39) 
 
50 (17.30) 
239 (82.70) 
0.0794 
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Abbreviations: LTBI: latent TB infection. HIV: human immunodeficiency virus. BMI: body mass index. 
TST: tuberculin skin test. 3HP-DOT: 3 months of directly observed, once-weekly rifapentine (maximum 
dose, 900 mg) plus isoniazid (maximum dose 300 mg); 9H-SAT, 9 months of daily self-administered 
isoniazid; LTBI: latent TB infection. HIV: human immunodeficiency virus. BMI: body mass index.  TST: 
tuberculin skin test. 
a  Median Two-Sample Test 
b Fisher’s exact test 
c Includes North American Indian and other participants in the United States and Canada. 
  d History of residing within a correctional institution for ≥ 1 month before enrollment.  
e Use: affirmative response to a question asking whether the participant ever drank alcoholic beverages. 
Abuse: score of ≥2 on the CAGE questionnaire.  
f Mantel-Haenszel Chi-Square 
 
 
 
 
 
 
 
Table 3. LTBI Treatment Completion, Stratified by Homelessness and by 
Treatment Regimen (n=6232) 
Treatment 
completion  
Homeless (n=505) 
 
Non-homeless (n=5727) 
3HP  
n=289 (%) 
9H  
n=216 (%) 
p-value 3HP  
n=2941 (%) 
9H  
n=2786 (%) 
p-value 
 
Completed 
 
227 (79) 
 
132 (61) 
<0.0001  
2435 (83) 
 
2032 (73) 
<0.0001 
 
Did not 
complete 
 
62 (21) 
 
84 (39) 
 
506 (17) 
 
754 (27) 
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Table 4A. Reasons for not Completing LTBI Treatment, Stratified by Homelessness 
Status Among Participants Assigned to the 9H Regimen (n=838) 
Reason category –no. (%) Homeless  
n=82  
Non-Homeless  
n=750  
Lost for more than 3 months 33 (40.24) 243 (32.40) 
Other 21 (25.61) 97 (12.93) 
Drug toxicities 10 (12.20) 119 (15.87) 
Patient refused therapy 9 (10.98) 161 (21.47) 
Patient withdrew consent 4 (4.88) 57 (7.60) 
Out of window 3(3.66) 33 (4.40) 
Prescription cancelled by MD 2 (2.44) 38 (5.07) 
Patient died 0(0) 2 (0.27) 
Missing  2 4 
 
 
           Table 4B. Reasons for not Completing Treatment, Stratified by Homelessness 
Status Among Participants Assigned to the 3HP Regimen (n=568) 
Reason category –no. (%) Homeless 
n=59  
Non-Homeless  
n=490  
Other 16 (27.12) 36 (7.35) 
Drug toxicities 12 (20.34) 169 (34.49) 
Lost for more than 3 months 12 (20.34) 44 (8.98) 
Patient refused therapy 11 (18.64) 172 (35.10) 
Out of window 4 (6.78) 13 (2.65) 
Prescription cancelled by MD 3(5.08) 11 (2.24) 
Patient withdrew consent 1 (1.69) 45 (9.18) 
Missing  3 16 
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Table 4C. Classification of “Other” Reason for Non-completion of Treatment in the 
9H Regimen, Stratified by Homeless Status (n=118) 
Reason Homeless (n=21) Non-homeless (n=97) 
   
Incarceration 6 9 
Moved 3 20 
Military deployment 0 5 
Lost 0 3 
Tx stopped 0 4 
School/ work conflicts 0 3 
Legal trouble 0 1 
Unable to obtain meds in 
rehab 
0 1 
Non-compliant 0 1 
MD wants to remove 
patient from study 
0 1 
No reason 12 49 
 
Table 4D. Classification of “Other” Reason for Non-completion of Treatment in the 
3HP Regimen, Stratified by Homeless Status (n=52) 
Reason Homeless (n=16) Non-homeless (n=36) 
   
Incarceration 3 6 
Moved 1 9 
Lost 1 1 
Non-compliant 0 2 
VISA expired 0 1 
Fleeing to Mexico due to 
legal trouble 
0 1 
Unknown 11 16 
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Table 5. Factors Associated with Non-completion of LTBI Treatment in Homeless 
Participants – Univariate Analysis (n=505) 
Factor  NCT 
(%) 
Odds 
Ratio 
Confidence 
Interval 
P-value 
Treatment 
Regimen 
3HP-DOT (n=216) 
Ref. 
9H-SAT (n=289)  
21.45 
38.89 
Ref. 
2.33 
Ref. 
1.57-3.45 
Ref. 
<0.001 
Age <38 (n=89) 
≥38 (n=416) Ref. 
32.58 
28.13 
1.24 
Ref. 
0.76-2.02 
Ref. 
0.40 
Ref. 
Sex Female (n=67) Ref. 
Male (n=438) 
25.37 
29.45 
Ref. 
1.23 
Ref. 
0.68-2.21 
Ref. 
0.49 
Race White (n=186) Ref. 
African descendent 
(n=268) 
Asian (n=11) 
Othera (n=40) 
32.80 
25.37 
27.27 
35 
Ref. 
0.70 
 
0.77 
1.10 
Ref. 
0.46-1.05 
 
0.20-3.00 
0.53-2.26 
Ref 
0.085 
 
0.705 
0.788 
Siteb Site 70 (n=17) Ref. 
Other sites (n=488) 
29.41 
28.89 
Ref. 
0.98 
Ref. 
0.34-2.82 
Ref. 
0.96 
Ethnicity Non-Hispanic 
(n=449) Ref. 
Hispanic (n=56) 
27.62 
39.29 
Ref. 
 
1.70 
Ref. 
 
0.96-3.01 
Ref. 
 
0.072 
HIV Status 
 
Negative (n=310) 
Ref. 
Positive (n=36) 
Unknown (n=159) 
29.68 
33.33 
26.42 
Ref. 
1.19 
0.85 
Ref. 
0.57-2.47 
0.55-1.31 
Ref. 
0.65 
0.46 
Birthplace Non-U.S (n=65)  
U.S. (n=440) Ref. 
38.46 
27.50 
1.65 
Ref. 
0.96-2.83 
Ref. 
0.07 
Ref. 
Body Mass 
Index 
 
Underweight (n=9) 
Normal (n=146) Ref. 
Overweight (199) 
Obesity (n=151) 
33.33 
33.56 
30.65 
21.85 
0.99 
Ref. 
0.88 
0.55 
0.24-4.13 
Ref. 
0.55-1.38 
0.33-0.93 
0.99 
Ref. 
0.57 
0.03 
Education 
 
≤8th grade (n=44) 
8th grade through 
some college 
(n=432) 
≥college degree 
(n=29) Ref. 
31.82 
28.70 
 
27.59 
1.23 
 
1.06 
Ref. 
0.44-3.44 
 
0.46-2.45 
Ref. 
0.70 
 
0.90 
Ref. 
Incarcerationc Yes (n=194)  
No (n=311) Ref.  
33.51 
26.05 
1.635 
Ref. 
0.97-2.12 
Ref. 
0.07 
Ref. 
Unemployed Yes (n=331)  
No (n=174) Ref. 
28.10 
30.46 
0.87 
Ref. 
0.60 – 1.33 
Ref. 
0.58 
Ref. 
Alcohol 
Consumptiond 
No (n=101) Ref. 
Use (n=223) 
Abuse (n=181) 
32.60 
24.22 
32.67 
Ref. 
0.66 
1.00 
Ref. 
0.39-1.10 
0.59-1.68 
Ref. 
0.11 
0.99 
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Factor  NCT 
(%) 
Odds 
Ratio 
Confidence 
Interval 
P-value 
Intravenous 
drug user ever  
No (n=394) Ref. 
Yes (n=111) 
29.19 
27.93 
Ref. 
0.94 
Ref. 
0.59-1.50 
Ref. 
0.80 
Smoking at 
Enrollment 
No (n=135) Ref.  
Yes (n=370) 
28.15 
29.19 
Ref. 
1.05 
Ref. 
0.68-1.63 
Ref. 
0.82 
Use of 
Methadone 
No (n=480) Ref. 
Yes (n=25) 
28.75 
32 
Ref. 
1.17 
Ref. 
0.49-2.77 
Ref. 
0.73 
Concomitant 
medications 
No (n=217) Ref. 
Yes (n=288) 
31.80 
26.74 
Ref. 
0.78 
Ref. 
0.53-1.15 
Ref. 
0.21 
LTBI for 
contact TB 
No (n=157) Ref. 
Yes (n=348) 
22.93 
31.61 
Ref. 
1.55 
Ref. 
1.01-2.40 
Ref. 
0.05 
LTBI for TST 
converter 
No (n=295) Ref. 
Yes (n=210) 
31.19 
25.71 
Ref.  
0.76 
Ref. 
0.51-1.13 
Ref. 
0.18 
LTBI fibrosis No (n=504) Ref. 
Yes (n=1) 
28.97 
0 
Ref. 
<0.001 
Ref. 
<0.001-
>999.999 
Ref. 
0.99 
LTBI for HIV 
infection 
No (n=472) Ref. 
Yes (n=33) 
29.03 
27.27 
Ref. 
0.92 
Ref. 
0.42-2.02 
Ref. 
0.83 
Chronic Liver 
Disease 
Yes (n=86) 
No (331) Ref. 
31.68 
28.22 
1.18 
Ref. 
0.74-1.89 
Ref. 
0.49 
Ref. 
Missed clinic 
visite 
No (n=453) Ref. 
Yes (n=52) 
25.17 
61.54 
Ref. 
4.76 
Ref. 
2.62-8.65 
Ref. 
<0.0001 
 
Abbreviations: 3HP-DOT, 3 months of directly observed, once-weekly rifapentine (maximum dose, 900 
mg) plus isoniazid (maximum dose 300 mg); 9H-SAT, 9 months of daily self-administered isoniazid;  
LTBI: latent TB infection. HIV: human immunodeficiency virus. BMI: body mass index.  TST: tuberculin 
skin test. NCT: non-completion of treatment 
a Includes North American Indian and other participants in the United States and Canada. 
b The variable site was categorized arbitrarily taking site with the highest number (70) as the reference.  
c History of residing within a correctional institution for ≥ 1 month before enrollment.  
d Use: affirmative response to a question asking whether the participant ever drank alcoholic beverages. 
Abuse: score of ≥2 on the CAGE questionnaire.  
e Missing ≥1 of the first 3 directly observed therapy (DOT) sessions for the 3HP regimen or ≥1 of the 3 monthly clinic  
  visits for the 9H regimen, followed by a DOT or a monthly visit, respectively. 
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Table 6. Factors Associated with Non-completion of LTBI Treatment Among 
Homeless Participants – Multivariate Analysis (N=505) 
Factor  NCT (%) Odds Ratio 
(95% CI) 
p-value 
Treatment 
regimen 
3HP (n=216) Ref. 
9H (n=289) 
12.28 
16.63 
Ref. 
2.11 (1.40, 
3.18) 
Ref. 
0.0003 
Birthplace in the 
US 
Non-US (n=65)  
US (n=440) Ref. 
23.96 
4.95 
1.96 (1.11, 
3.48) 
Ref. 
0.0220 
Ref. 
Incarceration a Yes (n=194) 
No (n=311) Ref. 
12.87 
16.04 
1.69 (1.11, 
2.57) 
Ref. 
0.0148 
Ref. 
Missed clinic visit 
b 
No (n=453) Ref. 
Yes (n=52) 
22.57 
6.34 
4.57 (2.46, 
8.49) 
Ref. 
<0.0001 
Ref. 
Abbreviations: NCT: non-completion of treatment; 3HP-DOT, 3 months of directly observed, once-
weekly rifapentine (maximum dose, 900 mg) plus isoniazid (maximum dose 300 mg); 9H-SAT, 9 
months of daily self-administered isoniazid 
a History of residing within a correctional institution for ≥ 1 month before enrollment.  
           b Missing ≥1 of the first 3 directly observed therapy (DOT) sessions for the 3HP regimen or ≥1 of the 3 monthly  
         clinic visits for the 9H regimen, followed by a DOT or a monthly visit, respectively. 
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Table 7. Homeless Participants Stratified by Regimen and Site (n = 505) 
Site 3HP  
n=289 (%) 
9H  
n=216 (%) 
   
G (n=181) 110 (21.78) 71 (14.06) 
L (n=78) 55 (10.89) 23 (4.55) 
C (n=57) 30 (5.94) 27 (5.35) 
J (n=40) 25 (4.95) 15 (2.97) 
N (n=42) 17 (3.37) 25 (4.95) 
V (n=17) 9 (1.78) 8 (1.58) 
D (n=12) 7 (1.39) 5 (0.99) 
T (n=7) 6 (1.19) 1 (0.20) 
U (n=14) 6 (1.19) 8 (1.58) 
P (n=13) 5 (0.99) 8 (1.58) 
E (n=9) 4 (0.79) 5 (0.99) 
R (n=6) 3 (0.59) 3 (0.59) 
B (n=7) 2 (0.40) 5 (0.99) 
H (n=2) 2 (0.40) 0 (0) 
O (n=8) 2 (0.40) 6 (1.19) 
A (n=1) 1 (0.20) 0 (0) 
F (n=4) 1 (0.20) 3 (0.59) 
I (n=2) 1 (0.20) 1 (0.20) 
K (n=2) 1 (0.20) 1 (0.20) 
M (n=1) 1 (0.20) 0 (0) 
Q (n=1) 1 (0.20) 0 (0) 
S (n=1) 0 (0) 1 (0.20) 
Total = 505  289 (8.94) 216 (7.20) 
                                 Site key: A=12, B=13, C=14, D=15, E=16, F=17, G=20, H=21, I=22, J=23, K=24, L=26, M=27, N=28, O=53,  
                                 P=54, Q=58, R=61, S=62, T=63, U=66, V=70 
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Table 8. Clusters of Participants Enrolled in the PREVENT TB Trial, 
Stratified by Homelessness Status (N=6232) 
 
Clusters 
Homeless 
(n=505) 
Non-Homeless 
(n=5727) 
1 399 (79.01) 4138 (72.25) 
2 19 (3.76) 653 (11.40) 
3 5 (0.99) 284 (4.96) 
4 12 (2.38) 220  (3.84) 
5 7 (1.39) 111 (1.94) 
6 0 (0) 63 (1.10) 
7 0 (0) 46 (0.80) 
8 1 (0.20) 42 (0.73) 
9 0 (0) 9 (0.16) 
10 7 (1.39) 23 (0.40) 
11 12 (2.38) 51 (0.89) 
12 0 (0) 24 (0.42) 
13 0 (0) 26 (0.45) 
14 0 (0) 7 (0.12) 
19 14 (2.77) 5 (0.09) 
23 0 (0) 23 (0.40) 
31 29  (5.74) 2 (0.03) 
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Table 9. Clusters of Homeless Participants Enrolled in the 
PREVENT TB Trial Stratified by Treatment Regimen (N=505) 
Cluster 3HP (n=289) 9H (n=216) 
1 200 (69.20) 199 (92.13) 
2 14 (4.84) 5 (2.31) 
3 5 (1.73) 0 (0) 
4 6 (2.08) 6 (2.78) 
5 2 (0.69) 5 (2.31) 
8 0 (0) 1 (0.46) 
10 7 (2.42) 0 (0) 
11 12 (4.15) 0 (0) 
19 14 (4.84) 0 (0) 
31 29 (10.03) 0 (0) 
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Table S1. Demographic Characteristics Among First Participants Enrolled in a 
Cluster, Stratified by Homeless Status (N=5173) 
Factor Homeless 
n=417 (%) 
Non-Homeless 
n=4756 (%) 
p-value 
Sex 
Male 
Female 
 
354 (84.89) 
63 (15.11) 
 
2487 (52.29) 
2269 (47.71) 
<0.001 
Age-years 
Median 
Interquartile range 
 
46 
40,52 
 
37 
28,47 
<0.001a 
Site b 
Site 70 
Other sites 
 
16 (3.84) 
401 (96.16) 
 
305 (6.41) 
4451 (93.59) 
<0.001 
Birthplace in the U. S.  
Yes 
No 
 
364 (87.29) 
53 (12.71) 
 
1879 (39.51) 
2877 (60.49) 
<0.001 
Race  
African descendent 
Asian 
White 
Other d 
 
243 (58.27) 
10 (2.40) 
154 (36.93) 
10 (2.40) 
 
1233(25.93) 
708 (14.89) 
2635 (55.40) 
180 (3.78) 
<0.001 
Ethnicity  
Hispanic 
Non-Hispanic 
 
45 (10.79) 
372 (89.21) 
 
1912 (40.20) 
2844 (59.80) 
<0.001 
BMI  
Median 
Interquartile range 
 
27 
(24, 30) 
 
27 
(24, 31) 
0.3005a 
 
 
BMI Category 
<18.5 
18.5 – 24.9 
25-29.9 
>30 
 
7 (1.68) 
123 (29.50) 
169 (40.53) 
118 (28.30) 
 
76 (1.60) 
1366 (28.72) 
1669 (35.09) 
1645 (34.59) 
0.0518 
Education category  
8th grade or less 
8th grade to some college 
College degree or greater 
 
37 (8.87) 
355 (85.13) 
25 (6) 
 
751 (15.79) 
2937 (61.75) 
1068 (22.46) 
<0.001 
History of incarceration e 
Yes 
No 
 
160 (38.37) 
257 (61.63) 
 
179 (3.76) 
4577 (96.24) 
<0.001 
Unemployment  
Yes 
No 
 
269 (64.51) 
148 (35.49) 
 
385 (8.10) 
4371 (91.90) 
<0.001 
Latent TB-contact  
Yes 
No 
 
261 (62.59) 
156 (37.41) 
 
2844 (59.80) 
1912 (40.20) 
0.2645 
Latent TB Fibrosis    <0.001b 
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Factor Homeless 
n=417 (%) 
Non-Homeless 
n=4756 (%) 
p-value 
Yes 
No 
1 (0.24) 
416 (99.76) 
177 (3.72) 
4579 (96.28) 
Latent TB – HIV positive  
Yes 
No 
 
33 (7.91) 
384 (92.09) 
 
105 (2.21) 
4651 (97.79) 
<0.001 
Latent TB –TST converter  
Yes 
No 
 
186 (44.60) 
231 (55.40) 
 
1913 (40.22) 
2843(59.78) 
0.0806 
HIV Status  
Positive 
Negative 
Unknown 
 
35 (8.39) 
246 (58.99) 
136 (32.61) 
 
108 (2.27) 
2359 (49.60) 
2289 (48.13) 
<0.001 
Smoking at Enrollment  
Yes 
No 
 
304 (72.90) 
113 (27.10) 
 
1306 (27.46) 
3450 (72.54) 
<0.001 
Alcohol Consumption f 
use 
abuse 
no 
 
187 (44.84) 
141 (33.81) 
89 (21.34) 
 
2338 (49.16) 
245 (5.15) 
2173 (45.69) 
<0.001g 
Injection Drug Use  
Yes 
No  
 
97 (23.26) 
320 (76.74) 
 
148 (3.11) 
4608 (96.89) 
<0.001 
 
Methadone treatment  
Yes 
No 
 
24 (5.76) 
393 (94.24) 
 
110 (2.31) 
4646 (97.69) 
<0.001 
Use of concomitant 
medications  
Yes 
No 
 
 
236 (56.59) 
181 (43.41) 
 
 
2414 (50.76) 
2342 (49.24) 
0.0222 
Use of a translator  
Yes 
No 
 
21 (5.04) 
396 (94.96) 
 
1150 (24.18) 
3606 (75.82) 
<0.001 
Liver disease  
Yes 
No 
 
86 (20.62) 
331 (79.38) 
 
136 (2.86) 
4620 (97.14) 
<0.001 
 
Abbreviations: LTBI: latent TB infection. HIV: human immunodeficiency virus. BMI: body mass index. 
TST: tuberculin skin test. 3HP-DOT, 3 months of directly observed, once-weekly rifapentine (maximum 
dose, 900 mg) plus isoniazid (maximum dose 300 mg); 9H-SAT, 9 months of daily self-administered 
isoniazid; LTBI: latent TB infection. HIV: human immunodeficiency virus. BMI: body mass index.  TST: 
tuberculin skin test. A cluster represents a group setting; clustered participants represent the first person in a 
cluster. This first person underwent randomization and is representative of all participants in the cluster. 
a  Median Two-Sample Test using the proc npar1way SAS procedure. 
b The variable site was categorized arbitrarily taking site with the highest number (70) as the reference 
c Fisher’s exact test 
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d Includes North American Indian and other participants in the United States and Canada. 
 e History of residing within a correctional institution for ≥ 1 month before enrollment.  
f Use: affirmative response to a question asking whether the participant ever drank alcoholic beverages. 
Abuse: score of ≥2 on the CAGE questionnaire.  
g Mantel-Haenszel Chi-Square 
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Table S2. Demographic Characteristics of the First Homeless Participants Enrolled 
in a Cluster, Stratified by Treatment Regimen (N= 417) 
Factor Treatment Regimen 
9H SAT 
n=204 (%) 
Treatment 
Regimen 
3HP DOT 
n=213 (%) 
p-value 
Cluster 
Yes 
No 
 
203 (99.5) 
1 (0.50) 
 
209 (98.12) 
4 (1.88) 
0.18 
Sex 
Male 
Female 
 
171 (83.82) 
33 (16.18) 
 
183 (85.92) 
30 (14.08) 
0.5510 
Age – years 
Median 
Interquartile range 
 
45.5 
40.5, 52.5 
 
47 
40, 52 
0.7358a 
Birthplace in the U.S. 
Yes 
No 
 
174 (85.29) 
30 (14.71) 
 
190 (89.20) 
23 (10.80) 
0.2311 
Race 
African descendent 
Asian 
White 
Otherc 
 
120 (58.82) 
6 (2.94) 
74 (36.27) 
4 (1.96) 
 
123 (57.75) 
4 (1.88) 
80 (37.56) 
6 (2.82) 
0.8330b 
Ethnicity  
Hispanic 
Non-Hispanic 
 
24 (53.33) 
180 (48.39) 
 
21 (46.67) 
192 (51.61) 
 
0.5307 
BMI  
Median 
Interquartile Range 
 
26 
(23, 29) 
 
27 
(24, 32) 
0.5944a 
 
BMI Category 
<18.5 
18.5 – 24.9 
25-29.9 
>30 
 
6 (2.94) 
68 (33.33) 
83 (40.69) 
47 (23.04) 
 
1 (0.47) 
55 (25.82) 
86 (40.38) 
71 (33.33) 
0.0208b 
 
 
 
Education category  
8th grade or less 
8th grade to some 
college 
College graduate or 
greater 
 
22 (10.78) 
166 (81.37) 
16 (7.84) 
 
15 (7.04) 
189 (88.73) 
9 (4.23) 
0.1011 
History of 
incarcerationd 
Yes 
 No 
 
75 (36.76) 
129 (63.24) 
 
85 (39.91) 
128 (60.09) 
0.5096 
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Factor Treatment Regimen 
9H SAT 
n=204 (%) 
Treatment 
Regimen 
3HP DOT 
n=213 (%) 
p-value 
Unemployment 
Yes 
No 
 
132 (64.71) 
72 (35.29) 
 
137 (64.32) 
76 (35.68) 
0.9343 
Latent TB contact 
Yes 
No 
 
125 (61.27) 
79 (38.73) 
 
137 (64.32) 
76 (35.68) 
0.5869 
Latent TB fibrosis 
Yes 
No 
 
0 (0) 
204 (100) 
 
1 (0.47) 
212 (99.53) 
0.5108e 
Latent TB HIV 
positive 
Yes 
No 
 
19 (9.31) 
185 (90.69) 
 
14 (6.57) 
199 (93.43) 
0.3000 
Latent TB TST 
converter 
Yes 
No 
 
89 (43.63) 
115 (56.37) 
 
97 (45.54) 
116 (54.46) 
0.6945 
HIV Status 
Positive 
Negative 
Unknown 
 
19 (9.31) 
119 (58.33) 
66 (32.35) 
 
17 (7.98) 
139 (65.26) 
57 (26.76) 
0.3453 
Smoking at 
Enrollment 
Yes 
No 
 
152 (74.51) 
52 (25.49) 
 
153 (71.83) 
60 (28.17) 
0.4696 
Alcohol 
Consumptione 
Use 
Abuse 
No 
 
88 (43.14) 
65 (31.86) 
51 (25) 
 
99 (46.48) 
76 (35.68) 
38 (17.84) 
0.1692f 
Injection drug use 
Yes 
No 
Unknown 
 
49 (24.02) 
155 (75.98) 
0 (0) 
 
48 (22.54) 
164 (77) 
1 (0.47) 
0.8614b 
Methadone treatment 
Yes 
No 
 
17 (8.33) 
187 (91.67) 
 
7 (3.29) 
206 (96.71) 
0.0270 
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Factor Treatment Regimen 
9H SAT 
n=204 (%) 
Treatment 
Regimen 
3HP DOT 
n=213 (%) 
p-value 
Use of a translator 
Yes 
No 
 
12 (5.88) 
192 (94.12) 
 
9 (4.23) 
204 (95.77) 
0.5055 
Liver disease 
Yes 
No 
 
49 (24.02) 
155 (75.98) 
 
37 (17.37) 
176 (82.63) 
0.0935 
  
Abbreviations: LTBI: latent TB infection. HIV: human immunodeficiency virus. BMI: body mass index. 
TST: tuberculin skin test. 3HP-DOT, 3 months of directly observed, once-weekly rifapentine (maximum 
dose, 900 mg) plus isoniazid (maximum dose 300 mg); 9H-SAT, 9 months of daily self-administered 
isoniazid; LTBI: latent TB infection. HIV: human immunodeficiency virus. BMI: body mass index.  TST: 
tuberculin skin test. A cluster represents a group setting; clustered participants represent the first person in a 
cluster. This first person underwent randomization and is representative of all participants in the cluster. 
a  Median Two-Sample Test using the proc npar1way SAS procedure. 
b Fisher’s exact test 
c Includes North American Indian and other participants in the United States and Canada. 
 d History of residing within a correctional institution for ≥ 1 month before enrollment.  
e Use: affirmative response to a question asking whether the participant ever drank alcoholic beverages. 
Abuse: score of ≥2 on the CAGE questionnaire.  
f Mantel-Haenszel Chi-Square  
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Table S3. Factors Associated with Non-completion of LTBI Treatment Among the 
First Homeless Participant Enrolled in a Cluster – Univariate Analysis (N=417) 
 
Factor  NCT 
(%) 
Odds 
Ratio 
Confidence 
Interval 
P-value 
Treatment 
Regimen 
3HP-DOT (n=204) Ref. 
9H-SAT (n=213)  
20.19 
38.73 
2.50 
Ref. 
1.61-3.87 
Ref. 
Ref. 
<0.001 
Age <38 (n=71) 
≥38 (n=346) Ref. 
31.43 
28.82 
1.13 
Ref. 
0.65-1.97 
Ref. 
0.66 
Ref. 
Sex Female (n=62) Ref. 
Male (n=355) 
23.81 
30.23 
Ref. 
1.39 
Ref. 
0.74-2.58 
Ref. 
0.30 
Race White (n=155) Ref. 
African descendent (n=242) 
Asian (n=10) 
Othera (n=10) 
32.47 
26.34 
30 
50 
Ref. 
0.74 
 
0.89 
2.08 
Ref. 
0.48-1.16 
 
0.22-3.59 
0.58-7.51 
Ref 
0.19 
 
0.87 
0.26 
Ethnicity Non-Hispanic (n=371) Ref. 
Hispanic (n=46) 
27.42 
44.44 
 
Ref. 
2.12 
Ref. 
1.13-3.98 
Ref. 
0.02 
Siteb Other sites (n=401) 
Site 70 (n=16) 
29.18 
31.25 
 
0.91 
Ref. 
0.31-2.67 
Ref. 
0.86 
Ref. 
HIV Status 
 
Negative (n=258) Ref. 
Positive (n=36) 
Unknown (n=123) 
31.40 
33.33 
23.58 
Ref. 
1.09 
0.67 
Ref. 
0.52-2.29 
0.41-1.10 
Ref. 
0.81 
0.12 
Birthplace Non-U.S (n=54)  
U.S. (n=363) Ref. 
43.40 
27.20 
2.05 
Ref. 
1.14-3.70 
Ref. 
0.02 
Ref. 
Body Mass 
Index 
 
Underweight (n=7) 
Normal (n=122) Ref. 
Overweight (168) 
Obesity (n=120) 
42.86 
33.33 
30.77 
22.03 
1.50 
Ref. 
0.89 
0.57 
0.32-7.02 
Ref. 
0.54-1.46 
0.32-1.00 
0.61 
Ref. 
0.64 
0.05 
Education 
 
≤8th grade (n=37) 
8th grade through some 
college (n=354) 
≥college degree (n=26) Ref. 
35.14 
28.73 
 
28 
1.39 
 
1.04 
Ref. 
0.46-4.20 
 
0.40-2.56 
Ref. 
0.56 
 
0.94 
Ref. 
Incarcerationc Yes (n=159)  
No (n=258) Ref. 
35.63 
25.29 
Ref. 
1.64 
Ref. 
1.07-2.51 
Ref. 
0.02 
Unemployed Yes (n=270) Ref. 
No (n=147) 
28.25 
31.08 
Ref. 
1.15 
Ref. 
0.74-1.77 
Ref. 
0.54 
Alcohol 
Consumptiond 
No (n=88) Ref. 
Use (n=188) 
Abuse (n=141) 
26.20 
31.21 
32.58 
Ref. 
0.74 
0.94 
Ref. 
0.42-1.27 
0.53-1.66 
Ref. 
0.27 
0.83 
Intravenous 
drug user ever  
No (n=320) Ref. 
Yes (n=97) 
30 
26.80 
Ref. 
0.85 
Ref. 
0.51-1.42 
Ref. 
0.54 
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Factor  NCT 
(%) 
Odds 
Ratio 
Confidence 
Interval 
P-value 
Smoking at 
Enrollment 
No (n=112) Ref.  
Yes (n=305) 
28.32 
29.61 
Ref. 
1.07 
Ref. 
0.66-1.72 
Ref. 
0.80 
Use of 
Methadone 
No (n=393) Ref. 
Yes (n=24) 
29.26 
29.17 
Ref. 
1.00 
Ref.  
0.40-2.47 
Ref. 
0.99 
Concomitant 
medications 
No (n=181) Ref. 
Yes (n=236) 
33.15 
26.27 
Ref. 
0.72 
Ref. 
0.47-1.10 
Ref. 
0.17 
LTBI for 
contact TB 
No (n=155) Ref. 
Yes (n=262) 
23.08 
32.95 
Ref. 
1.64 
Ref. 
1.04-2.58 
Ref. 
0.03 
LTBI for TST 
converter 
No (n=231) Ref. 
Yes (n=186) 
32.03 
25.81 
Ref. 
0.74 
Ref. 
0.48-1.13 
Ref. 
0.17 
LTBI fibrosis No (n=416) Ref. 
Yes (n=1) 
29.33 
0 
Ref. 
<0.001 
Ref. 
<0.001-
>999.999 
Ref. 
0.99 
LTBI for HIV 
infection 
No (n=384) Ref. 
Yes (n=33) 
29.43 
27.27 
Ref. 
0.90 
Ref. 
0.41-2.00 
Ref. 
0.79 
Missed clinic 
visite 
No (n=377) Ref. 
Yes (n=40) 
25.33 
64.29 
Ref. 
5.31 
Ref. 
2.71-10.40 
Ref. 
<0.001 
 
Abbreviations: NCT: non-completion of treatment; 3HP-DOT, 3 months of directly observed, once-
weekly rifapentine (maximum dose, 900 mg) plus isoniazid (maximum dose 300 mg); 9H-SAT, 9 
months of daily self-administered isoniazid; LTBI: latent TB infection. HIV: human immunodeficiency 
virus. BMI: body mass index.  TST: tuberculin skin test. A cluster represents a group setting; clustered 
participants represent the first person in a cluster. This first person underwent randomization and is 
representative of all participants in the cluster. 
a Includes North American Indian and other participants in the United States and Canada. 
b  The variable site was categorized arbitrarily taking site with the highest number (70) as the reference.  
c History of residing within a correctional institution for ≥ 1 month before enrollment.  
d Use: affirmative response to a question asking whether the participant ever drank alcoholic beverages. 
Abuse:  
  score of ≥2 on the CAGE questionnaire.  
        e Missing ≥1 of the first 3 directly observed therapy (DOT) sessions for the 3HP regimen or ≥1 of the 3 monthly  
       clinic visits for the 9H regimen, followed by a DOT or a monthly visit, respectively. 
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Table S4. Factors Associated with LTBI Non-completion of Treatment Among the 
First Participant Enrolled in a Cluster - Multivariate Analysis  (N=417) 
Factor Odds Ratio (95% CI) p-value 
Treatment Regimen 
 3HP  
9H 
 
Ref. 
2.23 (1.41, 3.53) 
 
 
0.0006 
Birthplace in the U.S. 
Yes 
No 
 
Ref. 
2.81 (1.48, 5.35) 
 
Ref. 
0.0016 
Incarceration a 
Yes 
No 
 
2.06 (1.28, 3.32) 
Ref. 
 
0.0029 
Missed clinic visit 
Yes 
No 
 
5.16  (2.55, 10.46) 
Ref. 
 
<0.0001 
        
Abbreviations: 3HP-DOT, 3 months of directly observed, once-weekly rifapentine (maximum dose, 900 
mg) plus isoniazid (maximum dose 300 mg); 9H-SAT, 9 months of daily self-administered isoniazid. A 
cluster represents a group setting; clustered participants represent the first person in a cluster. This first 
person underwent randomization and is representative of all participants in the cluster. 
a History of residing within a correctional institution for ≥ 1 month before enrollment.  
 
 
  
 
 
 
 
 
  
 
 
 
